{"id":"inhaled-long-acting-beta-agonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL575966","moleculeType":"Small molecule","molecularWeight":"361.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents activate beta-2 adrenergic receptors on bronchial smooth muscle, triggering increased intracellular cAMP and leading to smooth muscle relaxation and airway dilation. The long-acting formulation provides sustained bronchodilation, reducing airway obstruction and improving airflow. LABAs are typically used in combination with inhaled corticosteroids for maintenance therapy in chronic obstructive pulmonary disease and asthma.","oneSentence":"Long-acting beta-2 agonists bind to beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and bronchodilation with sustained effect over 12-24 hours.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:12.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"},{"name":"Asthma maintenance therapy"}]},"trialDetails":[{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT05935332","phase":"PHASE2","title":"Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma","status":"TERMINATED","sponsor":"RAPT Therapeutics, Inc.","startDate":"2023-07-05","conditions":"Asthma","enrollment":38},{"nctId":"NCT05851443","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-07-11","conditions":"Moderate to Severe Asthma","enrollment":240},{"nctId":"NCT07396987","phase":"NA","title":"Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation","status":"NOT_YET_RECRUITING","sponsor":"Juan Carlos Cardet","startDate":"2026-02","conditions":"Asthma Attack, Asthma Control, Asthma Exacerbations","enrollment":40},{"nctId":"NCT07396311","phase":"","title":"Fractional Exhaled Nitric Oxide and Exacerbations of COPD","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-03-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":120},{"nctId":"NCT06572228","phase":"PHASE4","title":"Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-08-26","conditions":"Asthma","enrollment":250},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":"Healthy","enrollment":81},{"nctId":"NCT07198880","phase":"NA","title":"Impact of Home Non Invasive Ventilation in Patients With Chronic Obstructive Pulmonary Disease Discharged From Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-01-01","conditions":"COPD, COPD (Chronic Obstructive Pulmonary Disease), Ventilation Therapy","enrollment":40},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT05111262","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-12-16","conditions":"Asthma, Nonadherence, Medication","enrollment":60},{"nctId":"NCT05919394","phase":"PHASE4","title":"Triple vs High Dose Inhaled CORticosteroids","status":"WITHDRAWN","sponsor":"Galaxia Empírica","startDate":"2023-06-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06721247","phase":"PHASE2, PHASE3","title":"Oral Intake of Mg in Controlled Asthmatic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2024-11-02","conditions":"Bronchial Asthma","enrollment":166},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT07030881","phase":"NA","title":"Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-06-20","conditions":"Asthma, COPD","enrollment":380},{"nctId":"NCT04456673","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-07-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":935},{"nctId":"NCT06552364","phase":"PHASE4","title":"Air Pollution and Inhaled Corticosteroids in COPD","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-04-01","conditions":"COPD","enrollment":48},{"nctId":"NCT06869382","phase":"PHASE4","title":"ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression","status":"COMPLETED","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2023-01-01","conditions":"Asthma Patients","enrollment":26},{"nctId":"NCT06657066","phase":"PHASE2, PHASE3","title":"EFFECTIVENESS of PROBIOTICS in ADULTS with MODERATE to SEVERE PERSISTENT ASTHMA","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2021-12-06","conditions":"Asthma Patients","enrollment":74},{"nctId":"NCT06567977","phase":"","title":"TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients","status":"RECRUITING","sponsor":"Chiesi Poland Sp. z o.o.","startDate":"2024-08","conditions":"Asthma","enrollment":60},{"nctId":"NCT00545844","phase":"PHASE4","title":"Singulair(R) In Asthma And Allergic Rhinitis (0476-383)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04-01","conditions":"Asthma","enrollment":313},{"nctId":"NCT03930732","phase":"PHASE3","title":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-04-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":939},{"nctId":"NCT05078021","phase":"","title":"Phenotyping Disease Severity in Asthma","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2022-04-21","conditions":"Asthma","enrollment":60},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT03527927","phase":"NA","title":"sTep dOWn Inhalers in the reAl woRlD","status":"COMPLETED","sponsor":"Hywel Dda Health Board","startDate":"2017-05-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":67},{"nctId":"NCT01108627","phase":"PHASE4","title":"Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists","status":"WITHDRAWN","sponsor":"Nemours Children's Clinic","startDate":"2010-10","conditions":"Safety of Long Acting Beta Agnoists","enrollment":""},{"nctId":"NCT00521222","phase":"NA","title":"Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes","status":"COMPLETED","sponsor":"Columbia University","startDate":"2007-06","conditions":"Asthma","enrollment":90},{"nctId":"NCT04265105","phase":"PHASE2, PHASE3","title":"Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-12-22","conditions":"Asthma","enrollment":18},{"nctId":"NCT04677959","phase":"PHASE4","title":"A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2021-02-16","conditions":"Asthma","enrollment":427},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT03546907","phase":"PHASE2","title":"Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-07-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":343},{"nctId":"NCT03265145","phase":"PHASE4","title":"Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":714},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT04138758","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"COPD","enrollment":42953},{"nctId":"NCT02512198","phase":"NA","title":"Electronic Prescription Data to Improve Primary Care Prescribing","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-07","conditions":"Physician's Practice Patterns","enrollment":236},{"nctId":"NCT03250689","phase":"PHASE2","title":"Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19},{"nctId":"NCT03478657","phase":"PHASE4","title":"An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-18","conditions":"Asthma","enrollment":222},{"nctId":"NCT00448812","phase":"NA","title":"AIR Extension Study - Long-Term Safety of Alair Treated Subjects","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2005-03","conditions":"Asthma","enrollment":69},{"nctId":"NCT01185275","phase":"","title":"A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-08","conditions":"Asthma","enrollment":133},{"nctId":"NCT03964220","phase":"","title":"Impact of Tiotropium Add-on Therapy in Patients With Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-15","conditions":"Asthma","enrollment":7857},{"nctId":"NCT00749411","phase":"PHASE2","title":"Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":61},{"nctId":"NCT04494321","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2017-06-19","conditions":"Asthma, COPD","enrollment":99},{"nctId":"NCT04456205","phase":"","title":"Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-01","conditions":"COPD, Inhaled Corticosteroid","enrollment":200},{"nctId":"NCT04322422","phase":"NA","title":"Clinical Characteristics and Treatment of Chest Tightness Variant Asthma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-06-01","conditions":"Asthma, Chest Syndrome, Clinical Anxiety","enrollment":300},{"nctId":"NCT02135692","phase":"PHASE3","title":"A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-29","conditions":"Asthma","enrollment":339},{"nctId":"NCT02251379","phase":"PHASE2","title":"Environmental Control as Add-on Therapy in Childhood Asthma","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-10-01","conditions":"Asthma","enrollment":155},{"nctId":"NCT04137029","phase":"NA","title":"Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, Pulmonology Scientific Research Institute","startDate":"2019-04-24","conditions":"Health, Subjective, Hyperreactivity, Bronchial","enrollment":20},{"nctId":"NCT01985334","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-14","conditions":"COPD","enrollment":4389},{"nctId":"NCT00808288","phase":"PHASE2","title":"A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive","enrollment":405},{"nctId":"NCT01248208","phase":"PHASE1, PHASE2","title":"FluMist in Egg Allergic Patients","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"2010-09","conditions":"Egg Allergy, Eligible for Vaccination Against Influenza","enrollment":17},{"nctId":"NCT03655392","phase":"NA","title":"Clinical, Functional and Inflammatory Evaluation in Asthmatic Patients After a Simple Short-Term Educational Program","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2015-07-01","conditions":"Asthma, Inflammation, Patient Relations, Nurse","enrollment":64},{"nctId":"NCT01342913","phase":"PHASE3","title":"A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":528},{"nctId":"NCT01017952","phase":"PHASE3","title":"A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1635},{"nctId":"NCT01313650","phase":"PHASE3","title":"A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1538},{"nctId":"NCT01053988","phase":"PHASE3","title":"A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1031},{"nctId":"NCT02014480","phase":"PHASE3","title":"A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT01323621","phase":"PHASE3","title":"Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":512},{"nctId":"NCT01313637","phase":"PHASE3","title":"A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1493},{"nctId":"NCT01772134","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":617},{"nctId":"NCT01899742","phase":"PHASE3","title":"The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":497},{"nctId":"NCT01054885","phase":"PHASE3","title":"Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1226},{"nctId":"NCT01777334","phase":"PHASE3","title":"The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":905},{"nctId":"NCT00200967","phase":"PHASE3","title":"Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2004-12","conditions":"Asthma","enrollment":87},{"nctId":"NCT01072149","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":54},{"nctId":"NCT01009463","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1626},{"nctId":"NCT01336608","phase":"PHASE3","title":"A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":446},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01323634","phase":"PHASE3","title":"Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":519},{"nctId":"NCT00315744","phase":"PHASE4","title":"Viapaed Study In Children And Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT01599871","phase":"PHASE3","title":"Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Hospital Son Espases","startDate":"2011-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":70},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT00964249","phase":"PHASE1","title":"Phase I Study of GW642444M in Healthy Japanese Male Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":32},{"nctId":"NCT00783003","phase":"PHASE1","title":"A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT02953041","phase":"PHASE4","title":"Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2016-10","conditions":"Asthma","enrollment":31},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT01437995","phase":"PHASE4","title":"Long-acting Beta Agonist Step Down Study","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-03","conditions":"Asthma","enrollment":459},{"nctId":"NCT01443845","phase":"PHASE4","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-30","conditions":"COPD, COPD Exacerbation, Lung Diseases","enrollment":2354},{"nctId":"NCT01772147","phase":"PHASE3","title":"Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":608},{"nctId":"NCT01376245","phase":"PHASE3","title":"A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":646},{"nctId":"NCT01248975","phase":"PHASE2","title":"Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Asthma","enrollment":145},{"nctId":"NCT00910689","phase":"PHASE4","title":"Drug and Non-Drug Treatment Of Severe Migraine","status":"COMPLETED","sponsor":"Ohio University","startDate":"2001-07","conditions":"Migraine Headache","enrollment":232},{"nctId":"NCT01948401","phase":"PHASE2","title":"A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07","conditions":"Asthma","enrollment":54},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT01961154","phase":"NA","title":"Stepping Down of Asthma Medication in Controlled Asthma","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2012-10","conditions":"Asthma","enrollment":56},{"nctId":"NCT02850484","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2016-03","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":99},{"nctId":"NCT02466347","phase":"PHASE1","title":"Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2014-06","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT01355991","phase":"PHASE1","title":"Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI","status":"UNKNOWN","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2011-08","conditions":"Spinal Cord Injury","enrollment":40},{"nctId":"NCT02547558","phase":"PHASE4","title":"Pulmonary Gas Exchange Response to Indacaterol in COPD","status":"UNKNOWN","sponsor":"Hospital Clinic of Barcelona","startDate":"2015-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":20},{"nctId":"NCT00974805","phase":"PHASE4","title":"An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Southampton","startDate":"2010-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48},{"nctId":"NCT01209715","phase":"PHASE2","title":"Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2010-10","conditions":"COPD","enrollment":""},{"nctId":"NCT02094274","phase":"PHASE1","title":"A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2013-11","conditions":"Asthma","enrollment":30},{"nctId":"NCT00909779","phase":"PHASE3","title":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT01697722","phase":"","title":"Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"1991-01","conditions":"Asthma","enrollment":815377},{"nctId":"NCT00712335","phase":"PHASE4","title":"The Effects of Montelukast on Smokers With Asthma","status":"COMPLETED","sponsor":"Inje University","startDate":"2007-02","conditions":"Asthmatic Smokers, Non-asthmatic Smokers","enrollment":105},{"nctId":"NCT00314574","phase":"PHASE3","title":"A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Asthma","enrollment":850},{"nctId":"NCT00403754","phase":"PHASE2","title":"Dose Ranging Study for Indacaterol in Japanese Asthma Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Asthma","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Inhaled Long-Acting Beta Agonist","genericName":"Inhaled Long-Acting Beta Agonist","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long-acting beta-2 agonists bind to beta-2 adrenergic receptors on airway smooth muscle, causing relaxation and bronchodilation with sustained effect over 12-24 hours. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}